Psychedelic Medicine Podcast with Dr. Lynn Marie Morski

In this episode, Dr. Sean M. Viña joins to discuss the ways that social inequality can impact psychedelic healing. Dr. Viña is a sociologist with a PhD from Indiana University whose research focuses on psychedelics and mental health, and social inequality.
In this conversation, Dr. Viña explains that while psychedelics are often framed as transformative treatments, their benefits appear unevenly distributed and frequently constrained by structural factors such as income inequality, education, stigma, caregiving burden, segregation, and social isolation. The discussion highlights how women—particularly single mothers—may experience diminished gains due to caregiving demands and stigmatization of mental illness, while Black and Latino populations show little measurable benefit once socioeconomic inequality is accounted for. Throughout, Dr. Viña emphasizes that outcomes are shaped less by the substances themselves than by the sociocultural environments people return to after treatment, underscoring the importance of community integration and structural supports alongside clinical care.
 
In this episode, you'll hear:
What inspired Dr. Viña to research social inequality and psychedelics
How caregiving burden, education, and stigma modulate women's mental health outcomes following psychedelic use
Why socioeconomic inequality appears to eliminate measurable benefits for many Black and Latino participants
The role of segregation, policing environments, and chronic stress in shaping treatment outcomes
Why American Indian populations respond better to psychedelic treatments in rural areas with greater access to nature and their culture
How having access to private versus public health insurance can impact psychedelic healing
Why focusing only on therapist–patient interactions may miss key determinants of success
Implications for designing more equitable psychedelic treatments and research
 
Quotes:
"Women who are highly educated actually seem to be getting about as much benefit [from psychedelic treatments] as men who are highly educated, but [lack of] education doesn't seem to negatively affect men the same way it affects women. Again, that's the pattern we see in all kinds of other health resources." [9:36]
"One of the studies that we did showed that if it wasn't for education and income differences, there would be a slight benefit [from psychedelics] for black participants in these surveys. But as soon as you accounted for education inequality and income inequality, it was wiped out." [21:40]
"I love the concept of the psychedelic renaissance, but when we start thinking about the statistics of who this is helping, this is a renaissance of less than 1% of people, right? This is a very small group of people who are getting benefits, just like many of the other resources that have come out in the past. … all these resources are probably valuable. They're all helpful. But there needs to be more than just the drug. There needs to be a bigger conversation about this society and the community that people are living in." [36:31]
 
Dr. Viña's academic articles:
"Medical Sociological and Epidemiological Psychedelics Paradigm", Drug Science Policy and Law, 2025
"A Community Centered Approach to Psychedelics", Discover Mental Health, 2025
"Unequal Healing: Gender, Psychedelics, and the Burden of Care", Women and Therapy, 2026
"Psychedelics and Mental Health Treatment Seeking Among Asians and Hawaiians", Psychoactives, 2025
"American Indian areas and psychedelics: A test of the minorities' diminished psychedelic returns", Journal of Rural Mental Health, 2025
"Religious Social Integration, Psychedelics, and Psychological Distress", Journal of Psychoactive Drugs, 2024
"Stigma, Psychedelic Use, and the Risk of Reduced Formal Mental Health Care", Stigma and Health, 2024
With Amanda L. Stephens: "Minorities' Diminished Psychedelic Returns." Drug Science, Policy and Law, 2023


Links:
Dr. Viña on LinkedIn
Dr. Viña on Researchgate
Previous episode: Psychedelics and Religion with Hunt Priest, MDiv
Psychedelic Medicine Association
Porangui

In this episode, Hunt Priest joins to discuss the intersection of psychedelic experiences and religion. Hunt is the founder of Ligare: A Christian Psychedelic Society and was a participant in the Johns Hopkins/NYU Psilocybin Study for Religious Leaders in 2016. The epiphanies he had at Hopkins forever changed the trajectory of his work and led him to start Ligare in 2021.
In this conversation, Hunt Priest reflects on how participating in the Johns Hopkins study reshaped his understanding of Christianity, embodiment, and spiritual experience. Drawing on his background as an Episcopal priest, he explores the deep resonance between psychedelic experiences and Christianity, arguing that non-ordinary states of consciousness have always been central to religious life, even if institutional churches have often marginalized them. The discussion ranges from spiritual emergence and theological disruption to healing, discernment, and the role clergy can play in preparation and integration. Hunt also shares his own profound embodied experience during the study where he encountered Vedic and Upanishadic concepts firsthand. He explains how it ultimately led him to found Ligare, a Christian psychedelic society aimed at bridging psychedelics, healing, and the Christian mystical tradition.
 
In this episode, you'll hear:
Hunt's ideas of how psychedelic experiences connect with Christian sacraments and liturgical practices
How psychedelics connect with understandings of religious pluralism and the diversity of spiritual experiences
Resources for working through ideas that psychedelic experiences could be sinful or demonic
Hunt's thoughts on navigating theological disruption, spiritual emergence, and expanded images of God
Why embodiment and bodily wisdom are central to spiritual insight and healing
The vital opportunity institutional religion risks missing in the current psychedelic renaissance
 
Quotes:
"I think there's a lot of us [clergy] out there that understand that the spiritual issues that come up with psychedelics are important and need to be tended to in a sensitive way—in an open minded way, an open hearted way." [14:36]
"The Church has, over time, taught people to not trust their minds or their bodies. And that's a huge mistake because our bodies keep the score and they also are one of the places we hold wisdom—which was the biggest lesson I got from the first experience I had at Hopkins." [17:39]
"That's why the spiritual care professionals could be so important: when these issues, these spirit big spiritual questions or even a collapse of your own theological framework happens, you need help to put it back together. And just like therapy helps us put our emotional life back together, I think a good spiritual director or spiritual advisor—one-on-one or small group work—can help us put our theology back together." [21:47]
 
Links:
Ligare website
Ligare on Instagram
Hunt on Instagram
Hunt on LinkedIn
Center for Action and Contemplation website
Previous episode: Avoiding the Pitfalls of Psychedelic Medicine with Matthew Johnson, PhD
Psychedelic Medicine Association
Porangui

In this encore episode of the Psychedelic Medicine Podcast, psychedelic science researcher and educator Dr. Manesh Girn discusses his studies investigating psychedelic brain action. Manesh earned PhD in neuroscience at McGill University and is an author on over a dozen peer-reviewed articles on psychedelics and related topics. He is also chief research officer at EntheoTech Bioscience and runs the YouTube channel the Psychedelic Scientist. 
In this conversation, Manesh discusses his recent article in Trends in Cognitive Sciences titled "A complex systems perspective on psychedelic brain action."He explains the complexity science approach used in the article, which emphasizes the brain is a holistic, interconnected system, rather than individual component networks that can be isolated. From this standpoint, Manesh critiques some simplistic explanations of the neural mechanisms of psychedelics which focus exclusively on interactions with the default mode network isolated from other brain systems.
He also explains how individual some of the neural effects of psychedelics are, citing different findings from different studies and observed variations between brain scans of different people. By better understanding these individual differences, and placing these different responses into a complexity science framework, Manesh believes that more individually-tailored psychedelic therapies are possible once the systems involved are more comprehensively understood. 
Manesh closes this discussion by explaining the difference between genuine complexity and sheer chaos.  Complexity, he explains, is a delicate balance of novelty and order, which is why psychedelic experiences can be both destabilizing and productive of novel insights and personal transformation. 
 
In this episode:
The research into psychedelics and the default mode network
Using frameworks from complexity science in psychedelic research
Measuring entropy in the brain
Differences in neurological effects from taking between different studies and different individuals
How a complexity science approach to neuroscience could better inform precision psychiatry
 
Quotes:
"You can't just look at a specific brain region or network [in psychedelic research], you've gotta talk about the brain as a whole, in this sense of seeing the brain as a system of interacting parts." [4:49]
"The core idea of this paper is that psychedelics put our brain into this state that is more dynamically flexible, it's more diverse in its activity patterns, and it's more sensitive to inputs that come in." [14:17]
"What we find in the brain imaging findings is that different studies disagree, but also if you look at individual people, they can have radically different effects on their brain—almost opposite." [21:37]
 
Links:
Manesh' recent article in Trends in Cognitive Sciences: "A complex systems perspective on psychedelic brain action"
​​Psilocybin vs Placebo Brain Connectivity Diagram from Dr. Robin Carhart-Harris
The Psychedelic Scientist YouTube Channel
The Psychedelic Scientist on Instagram
The Psychedelic Scientist on Twitter
Manesh on LinkedIn
EntheoTech website
Psychedelic Medicine Association
Porangui

In this episode, Will Van Derveer, MD joins to unpack what we know about which psychedelic medicines are best suited to particular mental health conditions. Dr. Van Derveer has trained several thousand mental health professionals in psychedelic-assisted psychotherapy, provided ketamine assisted therapy to hundreds of people, and has staffed MDMA therapy trials with MAPS. His book, Psychedelic Therapy: A Revolutionary Approach to Restoring Your Mental Health and Reclaiming Your Life, will be published by Shambala in the spring of 2026.
In this conversation, Dr. Van Derveer offers a clinician's framework for thinking through how different psychedelic medicines may align with different mental health conditions. He explores how factors such as anxiety levels, trauma history, prior psychedelic experience, and a person's orientation toward spiritual versus medical healing shape treatment decisions. Across discussions of anxiety, depression, PTSD, OCD, and eating disorders, Dr. Van Derveer reflects on the relative roles of ketamine, psilocybin, MDMA, and emerging short-acting psychedelics, while underscoring the importance of community, and integration. Throughout, he returns to a central theme: many conditions labeled as psychiatric may also reflect deeper forms of disconnection—social, existential, and spiritual—and psychedelic therapies can be powerful tools for restoring those lost connections when used thoughtfully.
 
In this episode, you'll hear:
Why safety, medication interactions, and psychiatric history must come before all other considerations
The difference between clinical and ceremonial approaches to psychedelic healing
Considering when group versus individual approaches to psychedelic therapy may be best suited for a particular patient
How ketamine, psilocybin, and MDMA may play distinct roles in treating anxiety and depression
Considerations of dose, tolerance, and maintenance sessions for ketamine treatments
Why MDMA-assisted therapy stands out for chronic and severe PTSD
Dr. Van Derveer's perspective on emerging psychedelic medicines and the future of treatment
 
Quotes:
"As time wears on, I lean more toward the group dynamic [for psychedelic therapy] because of the power of community and healing in community. And also, of course, it can help mitigate the cost of access for people." [8:24]
"There's a lot of conversation about ibogaine right now, and I think it's an incredibly powerful, beautiful, sacred, ancient medicine that has a role. But it has a lot more porcupine quills on it than, say, ketamine or MDMA." [27:16]
"In acute suicidality, I think ketamine is the treatment of choice. There's nothing like it. … it can be quite impressive how quickly suicidal thoughts melt away. But it is a short game because often it doesn't stick for people. And that's a huge drawback." [28:39]
"We know that there are clear associations between chronic depression and high levels of inflammation in the body and also in the brain. Ketamine and psilocybin both have strong anti-inflammatory effects. But it seems like somehow the pathways that psilocybin is working on… tends to produce longer term benefits." [30:10]
"I tend to think that spiritual connection—in whatever your language is, whatever your metaphors are, however you think about it—is something that we need to think about for health overall." [40:21]
 
Links:
Dr. Van Derveer on LinkedIn
Dr. Van Derveer on Instagram
Dr. Van Derveer on X
Dr. Van Derveer's forthcoming book, Psychedelic Therapy: A Revolutionary Approach to Restoring Your Mental Health and Reclaiming Your Life
Integrative Psychiatry Institution website 
Previous episode: Is Psilocybin Safe for Me? with Seth Mehr, MD
Psychedelic Medicine Association
Porangui

In this episode, Alicia Bigelow, ND joins to discuss the potential of psychedelic medicine to support the menopause transition. Dr. Ali Bigelow is a naturopathic physician, ketamine provider and licensed psilocybin facilitator in Portland, OR. She leads individual and group retreats, enjoys incorporating live music into her sessions when desired, and is passionate about supporting those navigating life transitions, such as end of life and menopause, through her low dose group, Menomorphosis. Dr. Bigelow will be doing retreats in 2026 with Rise Up Journeys at RiseUpJourneys.com
In this conversation, Dr. Bigelow explores the emerging intersection between psychedelics and the menopausal transition, framing perimenopause and menopause as profound neuroendocrine, psychological, and existential shifts rather than merely clinical syndromes. She also discusses how hormonal changes—particularly declining estrogen—interact with serotonin, inflammation, and neuroplasticity, potentially shaping psychedelic experiences and outcomes. Throughout the discussion, Dr. Bigelow emphasizes the unique capacity of psychedelics to support self-actualization, identity reformation, and meaning-making during midlife, especially when combined with hormone therapy, intentional integration practices, and strong community support.
 
In this episode, you'll hear:
Why perimenopause and menopause represent a major but under-recognized neurobiological life transition
How estrogen, serotonin receptors, and psychedelics like psilocybin may interact in midlife
What we know (and don't yet know) about hormone replacement therapy and psychedelic efficacy
The potential anti-inflammatory effects of psychedelics and their relevance to menopausal symptoms
How ketamine may function differently from classic psychedelics during hormonal transitions
Why psychedelics can support identity reorientation, self-actualization, and "not caring" in generative ways
The critical role of community, creativity, and nervous system regulation in integration during midlife
 
Quotes:
"We don't honor and celebrate aging and elderhood overall in our culture. … What I do feel is really vital is that we gather and support each other in all of life's transitions, and [menopause has] not only been underrepresented, but also just under honored." [3:29]
"As [estrogen] levels decrease, there's a decrease in serotonin receptors—which is the 5-HT2A receptor. And so that reduces our sensitivity to, and activity of serotonin. And psilocybin and LSD and other 5-HT2A agonists—they can enhance their receptors and the activity of those receptors." [13:20]
"The understanding is that with [estrogen] hormone replacement therapy you would then, theoretically, see a replenishment of [serotonin] receptors, and then the psilocybin would have more ability to act on those receptors." [15:37]
"Psilocybin—and psychedelics in general—and the menopausal transition are just really beautiful complements to each other and they become even more potent when used together." [19:48]
 
Links:
Dr. Bigelow on LinkedIn
Dr. Bigelow on Instagram
Dr. Bigelow's website
Synaptic Institute website 
Rise Up Journeys website 
Psychedelic Medicine Association
Porangui